JNJ Valuation Shifts as STELARA Drag Fades

Johnson & Johnson shares have outperformed the S&P 500 by a wide margin over the past year, rising approximately 57% against a 17% gain for the broader index. This performance has pushed the stock to roughly $270 per share, resulting in a trailing price-to-earnings multiple of 28.3 times. However, this metric reflects a period where the company’s flagship immunology drug, STELARA, faced intensifying competition that suppressed operational growth.

The apparent expensiveness of the valuation diminishes when examining forward estimates. Based on consensus net income for fiscal 2026, the multiple drops to 24.1 times, and it falls further to 20.9 times for 2027. This divergence suggests that the market is pricing in the recovery of margins once the temporary headwinds affecting STELARA subside, rather than reacting to the current, burdened earnings base.

STELARA Drag Distorts Recent Metrics

The trailing twelve-month results were compromised by the entry of biosimilars into the market. In the second quarter of 2026, STELARA accounted for a loss of 460 basis points in operational sales growth. Management attributes this decline to competitive pressure rather than underlying demand weakness for the therapy itself.

Excluding the impact of STELARA, Johnson & Johnson reported double-digit growth in the same quarter. The company’s broader portfolio remains robust, with total trailing twelve-month revenue approaching $98 billion. This stability is supported by a diverse range of assets, including 28 products and platforms that individually generate more than $1 billion in annual sales.

Immunology Segment Shows Mixed Performance

Within the immunology segment, performance is bifurcated. While STELARA faces declining revenue due to generic competition, the company’s newer asset, TREMFYA, is expanding rapidly. TREMFYA recorded a 71% increase in sales during the second quarter of 2026, maintaining its position as the fastest-growing advanced therapy for Crohn's disease and ulcerative colitis.

Margin Expansion Drives Forward Outlook

The lower forward multiples assume that profit will grow faster than revenue between 2026 and 2027. This projection relies on continued margin expansion, a trend already visible in recent data. The operating margin for the last twelve months stands at 26.8%, exceeding the three-year average of 25.7%.

Analysts project adjusted earnings per share of approximately $11.53 for 2026. This figure aligns closely with the company's own guidance, which sits at $11.60 to $11.75. The consistency between consensus estimates and management outlooks reinforces the view that the current share price reflects a normalized earnings trajectory rather than a speculative bubble.